Physician
Glendale Pathology Associates Medical Group of Glendale
Glendale Pathology Associates Medical Group of Glendale was paid $4.11M by Medicaid between Jan 2018 and Nov 2024, across 136 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 36% of everything it billed.
33Billing provider infoGLENDALE PATHOLOGY ASSOCIATES MEDICAL GROUP OF GLENDALE
GLENDALE, CA 91206
GLENDALE, CA 91206
33aNPI1053305797assigned 09/08/2005
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$4.11M
24GClaims963,348
24DCodes billed136
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in California
Rank by total paid#11 of 222
Median peer was paid$42K
This provider vs. median97×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 173,141 | $417K | |
| 2019 | 130,034 | $541K | |
| 2020 | 110,426 | $483K | |
| 2021 | 173,368 | $658K | |
| 2022 | 104,609 | $623K | |
| 2023 | 146,944 | $825K | |
| 2024incomplete | 124,826 | $565K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 36% | 39,646 | 37,602 | $1.48M |
| 88307 | 18% | 14,339 | 14,033 | $726K | |
| 88342 | 12% | 21,179 | 20,358 | $486K | |
| 88304 | 5.1% | 12,409 | 12,187 | $212K | |
| 80053 | Comprehensive metabolic panel | 3.9% | 114,836 | 67,018 | $160K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.4% | 147,979 | 80,903 | $139K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.8% | 8,090 | 7,924 | $74K |
| 88341 | 1.3% | 1,956 | 1,814 | $53K | |
| 88313 | 1.1% | 2,161 | 2,124 | $45K | |
| 83880 | 1.0% | 10,731 | 9,033 | $41K | |
| 84484 | <1% | 31,521 | 26,722 | $38K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 37,171 | 17,905 | $37K |
124 more codes
| 87040 | <1% | 16,689 | $36K | |
| 83735 | <1% | 36,647 | $34K | |
| 83605 | <1% | 30,712 | $34K | |
| 81001 | <1% | 61,103 | $23K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 5,159 | $23K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 25,153 | $23K |
| 83690 | <1% | 27,178 | $22K | |
| 88112 | <1% | 1,258 | $21K | |
| 86481 | <1% | 1,656 | $19K | |
| 84145 | <1% | 5,949 | $18K | |
| 82948 | <1% | 37,029 | $17K | |
| 88302 | <1% | 764 | $17K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,760 | $16K |
| 85730 | <1% | 19,253 | $16K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,203 | $15K |
| 88311 | <1% | 3,398 | $14K | |
| 85027 | <1% | 14,777 | $13K | |
| 80061 | Lipid panel | <1% | 7,604 | $12K |
| 86780 | <1% | 6,024 | $11K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,093 | $11K |
| 85610 | <1% | 21,617 | $10K | |
| 82805 | <1% | 1,862 | $10K | |
| 87186 | <1% | 7,791 | $9K | |
| 87641 | <1% | 2,275 | $9K | |
| 87077 | <1% | 6,207 | $8K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,313 | $8K |
| 85379 | <1% | 6,326 | $8K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 790 | $7K |
| 86140 | <1% | 11,086 | $7K | |
| 82962 | <1% | 2,845 | $7K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,542 | $7K |
| 84702 | <1% | 3,873 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,415 | $6K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 108 | $6K |
| 87081 | <1% | 6,016 | $5K | |
| 86480 | <1% | 501 | $5K | |
| 85007 | <1% | 11,129 | $4K | |
| 86901 | <1% | 11,331 | $4K | |
| 80202 | <1% | 2,283 | $4K | |
| 86300 | <1% | 633 | $4K | |
| 86900 | <1% | 9,645 | $4K | |
| 87070 | <1% | 3,071 | $3K | |
| 82247 | <1% | 4,557 | $3K | |
| 81025 | <1% | 2,962 | $3K | |
| 82378 | <1% | 1,041 | $3K | |
| 86803 | <1% | 1,572 | $3K | |
| 80076 | <1% | 3,907 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,048 | $3K |
| 85014 | <1% | 7,558 | $3K | |
| 88312 | <1% | 190 | $3K | |
| 80143 | <1% | 633 | $2K | |
| 80179 | <1% | 604 | $2K | |
| 83615 | <1% | 3,905 | $2K | |
| 86850 | <1% | 5,634 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 491 | $2K |
| 82728 | <1% | 1,864 | $2K | |
| 85060 | <1% | 206 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,757 | $2K |
| 82248 | <1% | 4,127 | $2K | |
| 82570 | <1% | 2,473 | $2K | |
| 85018 | <1% | 5,892 | $2K | |
| 87088 | <1% | 2,092 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 554 | $2K |
| 80074 | <1% | 280 | $2K | |
| 88333 | <1% | 37 | $2K | |
| 84466 | <1% | 792 | $1K | |
| 81003 | <1% | 4,639 | $1K | |
| 84703 | <1% | 2,323 | $1K | |
| 87340 | <1% | 927 | $1K | |
| 82140 | <1% | 638 | $1K | |
| 82746 | <1% | 596 | $1K | |
| 87400 | <1% | 1,730 | $1K | |
| 83540 | <1% | 1,204 | $1K | |
| 86923 | <1% | 181 | $1K | |
| 84439 | <1% | 983 | $960.00 | |
| 84156 | <1% | 1,697 | $899.89 | |
| 85651 | <1% | 2,499 | $896.23 | |
| 87807 | <1% | 923 | $861.16 | |
| 86880 | <1% | 919 | $820.17 | |
| 84100 | <1% | 1,296 | $793.37 | |
| 85384 | <1% | 952 | $747.16 | |
| 82010 | <1% | 749 | $744.31 | |
| 88300 | <1% | 134 | $712.95 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 589 | $695.37 |
| 87205 | <1% | 1,254 | $650.83 | |
| 82607 | <1% | 326 | $637.05 | |
| 82553 | <1% | 469 | $588.03 | |
| 88331 | <1% | 41 | $535.93 | |
| 85045 | <1% | 815 | $497.44 | |
| 82150 | <1% | 772 | $421.01 | |
| 82947 | <1% | 455 | $409.29 | |
| 82550 | <1% | 730 | $320.28 | |
| 85652 | <1% | 788 | $211.14 | |
| 86769 | <1% | 50 | $168.10 | |
| 87075 | <1% | 66 | $165.30 | |
| 86308 | <1% | 467 | $145.01 | |
| 80305 | <1% | 81 | $101.64 | |
| 86334 | <1% | 35 | $101.09 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 16 | $84.85 |
| 86762 | <1% | 39 | $81.08 | |
| 82803 | <1% | 56 | $73.89 | |
| 87116 | <1% | 30 | $59.84 | |
| 84480 | <1% | 41 | $54.21 | |
| 84300 | <1% | 75 | $53.33 | |
| 89051 | <1% | 19 | $50.44 | |
| 87071 | <1% | 61 | $49.98 | |
| 86701 | <1% | 26 | $33.12 | |
| 83935 | <1% | 29 | $28.74 | |
| 84481 | <1% | 15 | $28.25 | |
| 80164 | <1% | 17 | $25.08 | |
| 86703 | <1% | 12 | $23.87 | |
| 86317 | <1% | 14 | $22.11 | |
| 83550 | <1% | 14 | $20.86 | |
| 87210 | <1% | 13 | $19.10 | |
| 80069 | <1% | 32 | $17.96 | |
| 85520 | <1% | 28 | $15.04 | |
| 84157 | <1% | 27 | $11.70 | |
| 82950 | <1% | 15 | $11.54 | |
| 84550 | <1% | 20 | $9.20 | |
| 82945 | <1% | 13 | $8.06 | |
| 80329 | <1% | 85 | $7.73 | |
| 85347 | <1% | 29 | $3.72 | |
| 80050 | General health panel | 0% | 14 | $0.00 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOSGROVE, MICHELE (PRESIDENT)